Endocrinology

#Endocrinology #Financing #Immunology #OMass Therapeutics

OMass closes $310m oversubscribed financing round

Biotechnology company OMass Therapeutics has raised $310 million as part of an oversubscribed Series C financing round.  The funding will be used to support the advancement of the company’s lead programme into Phase II clinical development.   The company’s lead compound, OMS1620, is a potential best-in-class MC2 (melanocortin-2) receptor antagonist targeting congenital… Read More

#Business & Investment #News

#Confo Therapeutics #Endocrinology #Funding #GPCRs #Metabolomics

€1.6m grant supports drug discovery in metabolic diseases

Confo Therapeutics has been awarded a €1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The two-year grant will be used to expand Confo’s R&D efforts in the discovery of new medicines targeting Class B G protein-coupled receptors (GPCRs) using its patent-protected technology platform. Read More

#News

Peptide
#Endocrinology #FDA #Oncology #Orano Med #RadioMedix #Radiopharmaceuticals

First targeted alpha therapy receives breakthrough designation

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to AlphaMedix (212Pb-DOTAMTATE) for the treatment of adult patients with unresectable or metastatic, progressive somatostatin receptor expressing gastroenteropancreatic neuroendocrine tumours (GEP-NETs) who are naïve to peptide receptor radionuclide therapy (PRRT). AlphaMedix is a targeted alpha therapy currently in… Read More

#Cancer Research #News #Regulatory

Checking a baby's glucose levels
#Breast cancer #Drug repurposing #Endocrinology #Paediatrics #Sidra Medicine

Breast cancer drug repurposed for congenital hyperinsulinism

In a world first, Sidra Medicine, a member of Qatar Foundation, has pioneered a new treatment protocol for a young infant with congenital hyperinsulinism. The findings were published in the New England Journal of Medicine. As the patient wasn’t responding to conventional medical therapies, the Sidra… Read More

#News